Identification of U937(JAK3-M511I) Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor

Mutated JAK3 has been considered a promising target for cancer therapy. Activating mutations of JAK3 are observed in 3.9%–10% of acute myeloid leukemia (AML) patients, but it is unclear whether AML cells are sensitive to JAK3 inhibitors, and no disease-related human AML cell model has been reported....

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Hongfei, Wang, Jie, He, Rui, Yu, Xiuwen, Li, Shan, Huang, Jing, Li, Jie, Tang, Xia, Song, Xiaojuan, Tu, Zhengchao, Zhang, Zhang, Ding, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802890/
https://www.ncbi.nlm.nih.gov/pubmed/35111683
http://dx.doi.org/10.3389/fonc.2021.807200
Descripción
Sumario:Mutated JAK3 has been considered a promising target for cancer therapy. Activating mutations of JAK3 are observed in 3.9%–10% of acute myeloid leukemia (AML) patients, but it is unclear whether AML cells are sensitive to JAK3 inhibitors, and no disease-related human AML cell model has been reported. We have identified U937 as the first human AML cell line expressing the JAK3(M511I) activated mutation and confirmed that JAK3 inhibitors sensitively suppress the proliferation of U937 AML cells.

Ejemplares similares